Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.
San Francisco-based biotech company Alumis, formerly Esker Therapeutics, closed on a $200 million Series B financing round.
Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.
Investors Hand Disc Medicine $90 Million to Control Hematological Diseases Published: Sept. 2, 2021 By Heather McKenzie BioSpace A two-year-old biopharma company tackling rare blood diseases has received a $90 million infusion of cash. Disc Medicine, which is progressing a pipeline of clinical-stage therapies for hematologic illnesses including myelofibrosis and porphyrias, announced the Series […]
Swiss pharma giant Roche announced a partnership with Shape Therapeutics valued at more than $3 billion that will attempt to harness the Seattle-based company’s RNA editing platform to take on neurodegenerative diseases as well as others.
Three pharmaceutical and biotechnology companies announced the recent success of their respective funding rounds to support future efforts.
Shape Therapeutics generated $112 million from a recent Series B financing round the Seattle biotechnology firm co-led with Decheng Capital and Breton Capital.
The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
The first half of 2021 saw a flurry of IPOs as multiple companies make the move to become publicly traded.